Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling. Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; required for synergistic transcriptional activity in response to TGF-beta. Acts synergistically with SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. Binds to SMAD binding elements (SBEs) (5'-GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions. May act as a tumor suppressor. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. In muscle physiology, plays a central role in the balance between atrophy and hypertrophy. When recruited by MSTN, promotes atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 release and subsequent recruitment by the BMP pathway to promote hypertrophy via phosphorylated SMAD1/5/8.
Aviva Systems Biology總部位于加利福尼亞州圣迭戈,在中國(guó)北京設(shè)有辦公室,專注于為研究需求提供多克隆和單克隆抗體、ELISA試劑盒、蛋白質(zhì)和定制服務(wù)。Aviva Systems Biology生產(chǎn)了24,000種經(jīng)過(guò)驗(yàn)證的多克隆抗體,并提供近20,000種ELISA試劑盒,定制實(shí)驗(yàn)室服務(wù)包括蛋白表達(dá)和純化、抗體開(kāi)發(fā),以及ELISA的開(kāi)發(fā)、驗(yàn)證和生產(chǎn)。Aviva Systems Biology為與獨(dú)特物種和靶標(biāo)相關(guān)的研究提供獨(dú)特工具,研究領(lǐng)域包括轉(zhuǎn)錄因子、癌癥、心血管、細(xì)胞生物學(xué)、DNA損傷和修復(fù)、表觀遺傳學(xué)、信號(hào)轉(zhuǎn)導(dǎo)、細(xì)胞分化、干細(xì)胞生物學(xué)等等。